

Supply Chain Networks Against Time: From Food to Pharma

Anna Nagurney

John F. Smith Memorial Professor
Director – Virtual Center for Supernetworks
Isenberg School of Management
University of Massachusetts
Amherst, Massachusetts 01003

CEE Seminar Series

MIT, Cambridge, MA, December 9, 2015



Massachusetts
Institute of
Technology

Acknowledgments

Many thanks to Professor Carolina Osorio Pizano for inviting me to speak in your seminar series.

Special acknowledgments and thanks to my students and collaborators who have made research and teaching always stimulating and rewarding.

Support for Our Research Has Been Provided by:



National Science Foundation

THE ROCKEFELLER FOUNDATION

Fulbright Scholar Program **FULBRIGHT**



RADCLIFFE INSTITUTE FOR ADVANCED STUDY
HARVARD UNIVERSITY



AT&T Foundation



John F. Smith Memorial Fund
University of Massachusetts
Amherst



UNIVERSITY OF GOTHENBURG
SCHOOL OF BUSINESS, ECONOMICS AND LAW

Outline

- ▶ Background and Motivation
- ▶ Representation of Supply Chains as Networks
- ▶ Time as a Challenge and Competitive Advantage
- ▶ Methodology – The Variational Inequality Problem
- ▶ Supply Chain Networks - Optimization Models
 - ● Blood and Medical Nuclear Supply Chains
- ▶ Supply Chain Networks - Game Theory Models
 - ● Electric Power and Food Supply Chains
- ▶ The Pharmaceutical Industry, Issues, and a Full Model
- ▶ Supply Chain Network Competition in Quality
- ▶ Summary, Conclusions, and Suggestions for Future Research


Background and Motivation

Supply chains are the *critical infrastructure and backbones* for the production, distribution, and consumption of goods as well as services in our globalized *Network Economy*.

Supply chains, in their most fundamental realization, *consist of manufacturers and suppliers, distributors, retailers, and consumers at the demand markets*.

Today, supply chains may span thousands of miles across the globe, involve numerous suppliers, retailers, and consumers, and be underpinned by multimodal transportation and telecommunication networks.

A General Supply Chain



Examples of Supply Chains

- ▶ food and food products
- ▶ high tech products
- ▶ automotive
- ▶ energy (oil, electric power, etc.)
- ▶ clothing and toys
- ▶ healthcare supply chains
- ▶ humanitarian relief
- ▶ supply chains in nature.

Examples of Supply Chains



Characteristics of Supply Chains and Networks Today

- ▶ *large-scale nature* and complexity of network topology;
- ▶ *congestion*, which leads to nonlinearities;
- ▶ *alternative behavior of users of the networks*, which may lead to paradoxical phenomena;
- ▶ *possibly conflicting criteria associated with optimization*;
- ▶ *interactions among the underlying networks themselves*, such as the Internet with electric power networks, financial networks, and transportation and logistical networks;
- ▶ recognition of *their fragility and vulnerability*;
- ▶ policies surrounding networks today may have major impacts not only economically, but also *socially, politically, and security-wise*.

Supply Chains Are Network Systems

Supply chains are, in fact, *Complex Network Systems*.

Hence, *any formalism that seeks to model supply chains and to provide quantifiable insights and measures must be a system-wide one and network-based.*

Such crucial issues as the stability and resiliency of supply chains, as well as their adaptability and responsiveness to events in *a global environment of increasing risk and uncertainty* can only be rigorously examined from the view of supply chains as network systems.

Supply chains may be characterized by *decentralized decision-making* associated with the different economic agents or by *centralized* decision-making.

Representation of Supply Chains as Networks

Representation of Supply Chains as Networks

By depicting supply chains as networks, consisting of nodes, links, flows (and also associated functions and behavior) we can:

Representation of Supply Chains as Networks

By depicting supply chains as networks, consisting of nodes, links, flows (and also associated functions and behavior) we can:

- see **commonalities** and **differences** among supply chain problems and even other network problems;

Representation of Supply Chains as Networks

By depicting supply chains as networks, consisting of nodes, links, flows (and also associated functions and behavior) we can:


- see **commonalities** and **differences** among supply chain problems and even other network problems;
- avail ourselves, once the underlying functions (cost, profit, demand, etc.), flows (product, informational, financial, relationship levels, etc.), and constraints (nonnegativity, demand, budget, etc.), and the behavior of the decision-makers is identified, of **powerful methodological network tools for modeling, analysis, and computations**;

Representation of Supply Chains as Networks

By depicting supply chains as networks, consisting of nodes, links, flows (and also associated functions and behavior) we can:


- see **commonalities** and **differences** among supply chain problems and even other network problems;
- avail ourselves, once the underlying functions (cost, profit, demand, etc.), flows (product, informational, financial, relationship levels, etc.), and constraints (nonnegativity, demand, budget, etc.), and the behavior of the decision-makers is identified, of **powerful methodological network tools for modeling, analysis, and computations**;
- build meaningful extensions using the graphical/network conceptualization.

Representation of Supply Chains as Networks



The equivalence between supply chains and transportation networks established in Nagurney, *Transportation Research E* **42** (2006), 293-316.


Representation of Supply Chains as Networks




Multilevel supply chain established by Nagurney, Ke, Cruz, Hancock, and Southworth in *Environment & Planning B* **29** (2002), 795-818.

In 1952, Copeland in his book, *A Study of Moneyflows in the United States*, NBER, NY, asked whether money flows like water or electricity?

In 1956, Beckmann, McGuire, and Winsten in their classic book, *Studies in the Economics of Transportation*, Yale University Press, hypothesized that electric power generation and distribution networks could be transformed into transportation network equilibrium problems.




Transportation Network Equilibrium Reformulation of the Financial Network Equilibrium Model with Intermediation




Liu and Nagurney, *Computational Management Science* **4** (2007), 243-281.

Transportation Network Equilibrium Reformulation of Electric Power Supply Chains




The transportation network equilibrium reformulation of electric power supply chain networks by Nagurney, Liu, Cojocaru, and Daniele, *Transportation Research E* **43** (2007), 624-646.

We have shown that both electricity and money flow like transportation; the same holds for Internet flows.



Some of Our Books Related to Supply Chain Network Analysis and Design



Time as a Challenge and Competitive Advantage

Time as a Challenge and Competitive Advantage

- More knowledgeable (and demanding) consumers are expecting **timely deliveries**, despite, paradoxically, the **great distances that may be involved** from the producers to the consumers.



Time as a Challenge and Competitive Advantage

- More knowledgeable (and demanding) consumers are expecting **timely deliveries**, despite, paradoxically, the **great distances that may be involved** from the producers to the consumers.



- Delivery times are becoming a **strategy**, as important as **productivity, quality, and even innovation**.

Time as a Challenge and Competitive Advantage

Practitioners realize that **speed** and **consistency of delivery time** are two essential components of customer satisfaction, along with price. Amazon Prime members can get deliveries on same day as orders in 16 metropolitan areas and maybe some day via drones.



Stalk, Jr., in his *Harvard Business Review* 1988 article, "Time - The next source of competitive advantage," utilized the term **time-based competition**, to single out time as the major factor for sustained competitive advantage.

Time and Perishable Products

Added challenges arise in the case of *Perishable Products*, which, by definition, are time-sensitive.

Benjamin Franklin wrote in 1748 in his “Advice to a Young Tradesman,” *Remember that Time is Money*.

It may also be said that *time is life*, since time-sensitive products, such as vaccines and medicines, as well as, at the most fundamental level, food and water, are of a life-sustaining, if not, life-saving, nature.

Time and Perishable Products

Classical examples of perishable goods include fresh produce in the form of fruits and vegetables, meat and dairy products, medicines and vaccines, radioisotopes, cut flowers, and even human blood.

We take the broader perspective of products being perishable not only in terms of their characteristics (such as their chemistry and the underlying physics) and *supply* (that is, the manner of procurement/production/processing, storage, transportation, etc.) aspects, but also in terms of the *demand* for the products.

Time and Perishable Products

We include, under the *perishable product* umbrella, products that are *discarded* (or replaced) relatively quickly after purchase, because of changing consumer tastes, such as *fast fashion apparel*, or those that become obsolete (as in *certain high technology products*).

Such an approach follows from Whitin (1957), who considered the deterioration of fashion goods at the end of a prescribed shortage period.

Time and Perishable Products

Supply chain management of perishable products at the strategic, tactical, and operational levels of the decision-making hierarchy is faced with such challenges as:

Time and Perishable Products

Supply chain management of perishable products at the strategic, tactical, and operational levels of the decision-making hierarchy is faced with such challenges as:

- ▶ *Transportation and storage*: Many perishable products require careful handling, special transportation equipment, and cold storage facilities to ensure product quality (and quantity).

Time and Perishable Products

Supply chain management of perishable products at the strategic, tactical, and operational levels of the decision-making hierarchy is faced with such challenges as:

- ▶ *Transportation and storage*: Many perishable products require careful handling, special transportation equipment, and cold storage facilities to ensure product quality (and quantity).
- ▶ *Inventory management*: At the demand points and at other supply chain facilities, inventory tracking and replenishment techniques may need to be utilized to minimize outdating.

Time and Perishable Products

Supply chain management of perishable products at the strategic, tactical, and operational levels of the decision-making hierarchy is faced with such challenges as:

- ▶ *Transportation and storage*: Many perishable products require careful handling, special transportation equipment, and cold storage facilities to ensure product quality (and quantity).
- ▶ *Inventory management*: At the demand points and at other supply chain facilities, inventory tracking and replenishment techniques may need to be utilized to minimize outdating.
- ▶ *Incurred waste discarding cost*: Discarding of the waste may impose additional costs.

Time and Perishable Products

Supply chain management of perishable products at the strategic, tactical, and operational levels of the decision-making hierarchy is faced with such challenges as:

- ▶ *Transportation and storage*: Many perishable products require careful handling, special transportation equipment, and cold storage facilities to ensure product quality (and quantity).
- ▶ *Inventory management*: At the demand points and at other supply chain facilities, inventory tracking and replenishment techniques may need to be utilized to minimize outdating.
- ▶ *Incurred waste discarding cost*: Discarding of the waste may impose additional costs.
- ▶ *Safety and environmental impact*: Perished products and the associated waste may be hazardous and may pollute.

Time and Perishable Products

Supply chain management of perishable products at the strategic, tactical, and operational levels of the decision-making hierarchy is faced with such challenges as:

- ▶ *Transportation and storage*: Many perishable products require careful handling, special transportation equipment, and cold storage facilities to ensure product quality (and quantity).
- ▶ *Inventory management*: At the demand points and at other supply chain facilities, inventory tracking and replenishment techniques may need to be utilized to minimize outdating.
- ▶ *Incurred waste discarding cost*: Discarding of the waste may impose additional costs.
- ▶ *Safety and environmental impact*: Perished products and the associated waste may be hazardous and may pollute.
- ▶ *Demand management*: Demand may be uncertain or known (as in scheduled treatments) and fixed. It may be price-sensitive (fashion apparel, consumer goods and pharma).

Methodology - The Variational Inequality Problem

Methodology - The Variational Inequality Problem

We utilize the theory of variational inequalities for the formulation, analysis, and solution of both centralized and decentralized supply chain network problems.

Definition: The Variational Inequality Problem

The finite-dimensional variational inequality problem, $VI(F, \mathcal{K})$, is to determine a vector $X^ \in \mathcal{K}$, such that:*

$$\langle F(X^*), X - X^* \rangle \geq 0, \quad \forall X \in \mathcal{K},$$

where F is a given continuous function from \mathcal{K} to R^N , \mathcal{K} is a given closed convex set, and $\langle \cdot, \cdot \rangle$ denotes the inner product in R^N .

Methodology - The Variational Inequality Problem

The vector X consists of the decision variables – typically, the flows (products, prices, etc.).

\mathcal{K} is the feasible set representing how the decision variables are constrained – for example, the flows may have to be nonnegative; budget constraints may have to be satisfied; similarly, quality and/or time constraints may have to be satisfied.

The function F that enters the variational inequality represents functions that capture the behavior in the form of the functions such as costs, profits, risk, etc.


The variational inequality problem contains, as special cases, such mathematical programming problems as:

- systems of equations,
- optimization problems,
- complementarity problems,
- game theory problems, operating under Nash equilibrium,
- and is related to the fixed point problem.

Hence, it is a natural methodology for a spectrum of supply chain network problems from centralized to decentralized ones as well as to design problems.

Geometric Interpretation of $\text{VI}(F, \mathcal{K})$ and a Projected Dynamical System (Dupuis and Nagurney, Nagurney and Zhang)

In particular, $F(X^*)$ is “orthogonal” to the feasible set \mathcal{K} at the point X^* .



Associated with a VI is a Projected Dynamical System, which provides natural underlying dynamics associated with travel (and other) behavior to the equilibrium.


To model the *dynamic behavior of complex networks*, including supply chains, we utilize *projected dynamical systems* (PDSs) advanced by Dupuis and Nagurney (1993) in *Annals of Operations Research* and by Nagurney and Zhang (1996) in our book *Projected Dynamical Systems and Variational Inequalities with Applications*.

Such nonclassical dynamical systems are now being used in *evolutionary games* (Sandholm (2005, 2011)), *ecological predator-prey networks* (Nagurney and Nagurney (2011a, b)), and even *neuroscience* (Girard et al. (2008) *dynamic spectrum model for cognitive radio networks* (Setoodeh, Haykin, and Moghadam (2012))).

A Multidisciplinary Perspective for Perishable Product Supply Chains

In our research on perishable and time-sensitive product supply chains, we utilize results from physics, chemistry, biology, and medicine in order to capture the perishability of various products over time from food to healthcare products such as blood, medical nucleotides, and pharmaceuticals.

A variety of perishable product supply chain models, computational procedures, and applications can be found in our new book:



Supply Chain Networks – Optimization Models

Blood Supply Chains for the Red Cross

A. Nagurney, A. H. Masoumi, and M. Yu, "Supply Chain Network Operations Management of a Blood Banking System with Cost and Risk Minimization," *Computational Management Science* **9(2)** (2012), 205-231.



Blood Supply Chains for the Red Cross

- ▶ The shelf life of platelets is 5 days and of red blood cells is 42.
- ▶ Over 39,000 donations are needed everyday in the U.S., and the blood supply is frequently reported to be just 2 days away from running out (American Red Cross (2010)).
- ▶ Some hospitals have delayed surgeries due to blood shortages on 120 days in a year (Whitaker et al. (2007)).
- ▶ The national estimate for the number of units blood products outdated by blood centers and hospitals was 1,276,000 out of 15,688,000 units (Whitaker et al. (2007)).

The American Red Cross is the major supplier of blood products to hospitals and medical centers satisfying over 45% of the demand for blood components nationally (Walker (2010)).



Blood Supply Chains for the Red Cross

The hospital cost of a unit of red blood cells in the U.S. had a **6.4%** increase from 2005 to 2007.

In the U.S., this criticality has become more of an issue in the **Northeastern** and **Southwestern** states since this cost is meaningfully higher compared to that of the Southeastern and Central states.



Supply Chain Network Topology for a Regionalized Blood Bank



ARC Regional Division

Blood Collection Sites

Blood Centers

Component Labs

Storage Facilities

Distribution Centers

Demand Points

Blood Supply Chains for the Red Cross

We developed a supply chain network optimization model for the management of the procurement, testing and processing, and distribution of a perishable product – that of human blood.

Novel features of the model include:

- ▶ It captures *perishability of this life-saving product* through the use of arc multipliers;
- ▶ It contains *discarding costs* associated with waste/disposal;
- ▶ It handles *uncertainty* associated with demand points;
- ▶ It assesses *costs associated with shortages/surpluses at the demand points*, and
- ▶ It quantifies the *supply-side risk* associated with procurement.

Medical Nuclear Supply Chains

We developed a medical nuclear supply chain network design model which captures the decay of the radioisotope molybdenum.

"Medical Nuclear Supply Chain Design: A Tractable Network Model and Computational Approach," A. Nagurney and L.S. Nagurney, *International Journal of Production Economics* **140**(2) (2012), 865-874.



Medical Nuclear Supply Chains

In our medical nuclear supply chain models we capture the radioactive decay through the use of arc multipliers.

Hence, the framework for both our blood supply chain work and medical nuclear work is that of *generalized* networks.

We will highlight how this is done in a full developed game theory model for pharmaceuticals later in this presentation.

Medical Nuclear Supply Chains

Medical nuclear supply chains are essential supply chains in healthcare and provide the conduits for products used in nuclear medical imaging, which is routinely utilized by physicians for diagnostic analysis for both cancer and cardiac problems.

Such supply chains have unique features and characteristics due to the products' time-sensitivity, along with their hazardous nature.

Salient Features:

- ▶ complexity
- ▶ economic aspects
- ▶ underlying physics of radioactive decay
- ▶ importance of considering both waste management and risk management.

Medical Nuclear Supply Chains

Over 100,000 hospitals in the world use radioisotopes (World Nuclear Association (2011)).


Technetium, ^{99m}Tc , which is a decay product of Molybdenum-99, ^{99}Mo , is the most commonly used medical radioisotope, used in more than 80% of the radioisotope injections, with more than 30 - 40 million procedures worldwide each year.

The half-life of Molybdenum-99 is 66.7 hours and that of Technetium is 6 hours.

Each day, 41,000 nuclear medical procedures are performed in the United States using Technetium-99m.

Medical Nuclear Supply Chains

A **radioactive isotope** is bound to a pharmaceutical that is injected into the patient and travels to the site or organ of interest in order to construct an image for **medical diagnostic** purposes.



Medical Nuclear Supply Chains

For over two decades, all of the Molybdenum necessary for U.S.-based nuclear medical diagnostic procedures has come from foreign sources.



Medical Nuclear Supply Chains

⁹⁹Mo Supply Chain Challenges:

- ▶ The majority of the reactors are between 40 and 50 years old. Several of the reactors currently used are due to be retired by the end of this decade(Seeverens (2010) and OECD Nuclear Energy Agency (2010a)).

Medical Nuclear Supply Chains

⁹⁹Mo Supply Chain Challenges:

- ▶ The majority of the reactors are between 40 and 50 years old. Several of the reactors currently used are due to be retired by the end of this decade(Seeverens (2010) and OECD Nuclear Energy Agency (2010a)).
- ▶ Limitations in processing capabilities make the world critically vulnerable to Molybdenum supply chain disruptions.

Medical Nuclear Supply Chains

⁹⁹Mo Supply Chain Challenges:

- ▶ The majority of the reactors are between 40 and 50 years old. Several of the reactors currently used are due to be retired by the end of this decade(Seeverens (2010) and OECD Nuclear Energy Agency (2010a)).
- ▶ Limitations in processing capabilities make the world critically vulnerable to Molybdenum supply chain disruptions.
- ▶ The number of generator manufacturers is under a dozen (OECD Nuclear Energy Agency (2010b)).

Medical Nuclear Supply Chains

⁹⁹Mo Supply Chain Challenges:

- ▶ The majority of the reactors are between 40 and 50 years old. Several of the reactors currently used are due to be retired by the end of this decade(Seeverens (2010) and OECD Nuclear Energy Agency (2010a)).
- ▶ Limitations in processing capabilities make the world critically vulnerable to Molybdenum supply chain disruptions.
- ▶ The number of generator manufacturers is under a dozen (OECD Nuclear Energy Agency (2010b)).
- ▶ Long-distance transportation of the product raises safety and security risks, and also results in greater decay of the product.




Figure 1: The Medical Nuclear Supply Chain Network Topology

Arc Multipliers

Because of the exponential decay of molybdenum, we have that the quantity of the radioisotope:

$$N(t) = N_0 e^{-\lambda t}$$

so that an arc multiplier on a link a that takes t_a hours of time corresponds to:

$$\alpha_a = e^{-\frac{\ln 2}{66.7} t_a}.$$

Supply Chain Networks – Game Theory Models

Electric Power Supply Chains

We developed *an empirical, large-scale electric supply chain network equilibrium model*, formulated it as a VI problem, and were able to solve it by *exploiting the connection between electric power supply chain networks and transportation networks* using our proof of a hypothesis posed in the classic book, *Studies in the Economics of Transportation*, by Beckmann, McGuire, and Winsten (1956).

The paper, “An Integrated Electric Power Supply Chain and Fuel Market Network Framework: Theoretical Modeling with Empirical Analysis for New England,” by Zugang Liu and Anna Nagurney was published in *Naval Research Logistics* **56** (2009), 600-624.


An Empirical Example of an Electric Power Supply Chain for New England

There are 82 generating companies who own and operate 573 generating units. We considered 5 types of fuels: natural gas, residual fuel oil, distillate fuel oil, jet fuel, and coal. The whole area was divided into 10 regions:


1. Maine
2. New Hampshire
3. Vermont
4. Connecticut (excluding Southwest Connecticut)
5. Southwestern Connecticut (excluding the Norwalk-Stamford area)
6. Norwalk-Stamford area
7. Rhode Island
8. Southeastern Massachusetts
9. Western and Central Massachusetts
10. Boston/Northeast Massachusetts.

Graphic of New England

1. Maine
2. New Hampshire
3. Vermont
4. Connecticut (excluding Southwestern Connecticut)
5. Southwestern Connecticut (excluding the Norwalk-Stamford area)
6. Norwalk-Stamford area
7. Rhode Island
8. Southeastern Massachusetts
9. Western and Central Massachusetts
10. Boston/Northeastern Massachusetts




The Electric Power Supply Chain Network with Fuel Supply Markets



We tested the model on the data of July 2006 which included $24 \times 31 = 744$ hourly demand/price scenarios. We sorted the scenarios based on the total hourly demand, and constructed the load duration curve. We divided the duration curve into 6 blocks ($L_1 = 94$ hours, and $L_w = 130$ hours; $w = 2, \dots, 6$) and calculated the average regional demands and the average weighted regional prices for each block.

The empirical model had on the order of 20,000 variables.

Actual Prices Vs. Simulated Prices (\$/Mwh)




Sensitivity Analysis

We used the same demand data, and then varied the prices of natural gas and residual fuel oil. We assumed that the percentage change of distillate fuel oil and jet fuel prices were the same as that of the residual fuel oil price.

The next figure presents the average electricity price for the two peak blocks under oil/gas price variations.

The surface in the figure represents the average peak electricity prices under different natural gas and oil price combinations.

Sensitivity Analysis











Food Supply Chains


Food is something anyone can relate to.



Fascinating Facts About Food Perishability

THE SHELF LIFE OF FOOD			
Foods unopened, uncut or uncooked unless stated otherwise	COUNTER/PANTRY	REFRIGERATOR	FREEZER
	1 DAY ← → 1 MONTH	1 DAY ← → 3 MONTHS	1 MONTH ← → 1 YEAR
 APPLES	2-4 weeks	1-2 months	8-12 months
 BANANAS	2-7 days	5-9 days	2-3 months
 CANTALOUPE	Until ripe	1 week	8-12 months
 CARROTS	Up to 4 days	4-5 weeks	8-12 months
 CUCUMBERS	1-3 days	1 week	8-12 months
 EGGS	Few hours	3-4 weeks	Do not freeze
 MILK	Few hours	5-7 days	1 month
 YOGURT	Few hours	2-3 weeks	1-2 months

Fascinating Facts About Food Perishability



Source: Food and Agriculture Organization 2011

Fascinating Facts About Food Perishability

**ABOUT 10 PERCENT OF THE
U.S. ENERGY BUDGET GOES TO
BRINGING FOOD TO OUR TABLES.**

Source: Webber, Michael, "How to Make the Food System More Energy Efficient," *Scientific American*, December 29, 2011.



**ONE INDUSTRY CONSULTANT
ESTIMATES THAT UP TO ONE
IN SEVEN TRUCKLOADS OF
PERISHABLES DELIVERED TO
SUPERMARKETS IS THROWN AWAY.**

Source: Beswick, P. et al, "A Retailer's Recipe for Fresher Food and Far Less Shrink," Oliver Wyman, [Boston. ergpeditorial.biz/worksamples/OW%20grocery%20shrinkage.pdf](http://www.oliverwyman.com/worksamples/OW%20grocery%20shrinkage.pdf).

**FOR THE AVERAGE U.S. HOUSEHOLD OF
FOUR, FOOD WASTE TRANSLATES INTO
AN ESTIMATED \$1,350 TO \$2,275 IN
ANNUAL LOSSES.**



Source: Bloom, American Household, 187. Another report using updated USDA consumer loss numbers and 2011 prices estimates \$1,600 in annual losses per household of four. Clean Metrics, "The Climate Change and Economic Impacts of Food Waste in the United States," <http://www.cleanmetrics.com/wp-content/uploads/2012/01/foodwaste.pdf>

Source: Food and Agriculture Organization 2011


Fresh Produce Food Supply Chains

We developed a fresh produce supply chain network oligopoly model that

1. captures the deterioration of fresh food along the entire supply chain from a network perspective;
2. handles the exponential time decay through the introduction of arc multipliers;
3. formulates oligopolistic competition with product differentiation;
4. includes the disposal of the spoiled food products, along with the associated costs;
5. allows for the assessment of alternative technologies involved in each supply chain activity.

Reference: “Competitive Food Supply Chain Networks with Application to Fresh Produce,” Min Yu and Anna Nagurney, *European Journal of Operational Research* **224(2)** (2013), 273-282.

Fresh Produce Food Supply Chains



Fresh Produce Food Supply Chains

Food products also deteriorate over time and especially fresh produce. According to Nahmias (1982), each unit has a probability of $e^{\lambda t_a}$ of surviving t_a units of time where λ is the decay rate. Hence, arc multipliers can be constructed in a similar manner as those for the medical nuclear supply chain:

$$\alpha_a = e^{-\lambda t_a}$$

where λ is the decay rate for the food.

In rare cases, food deterioration follows the zero order reactions with linear decay (see Tijssens and Polderdijk (1996) and Rong, Akkerman, and Grunow (2011)). Then,

$$\alpha_a = 1 - \lambda t_a$$

for a post-production link.

The Pharmaceutical Industry, Issues, and a Full Model

The Pharmaceutical Industry

Pharmaceutical, that is, medicinal drug, manufacturing is *an immense global industry*.

In 2008, the global pharmaceutical revenue came to some \$712 billion based on quarterly exchange rates. In 2014, the total revenues of the pharmaceutical market stood at almost \$940 billion worldwide (Statista (2015)).

In 2014, the total spending in the U.S. on medicines was \$372 billion.

The Pharmaceutical Industry

Although pharmaceutical supply chains have begun to be coupled with sophisticated technologies in order to improve both the quantity and the quality of their associated products, despite all the advances in manufacturing, storage, and distribution methods, *pharmaceutical drug companies are far from effectively satisfying market demands on a consistent basis.*

In fact, it has been argued that pharmaceutical drug supply chains are *in urgent need of efficient optimization techniques in order to reduce costs and to increase productivity and responsiveness* (Shah (2004) and Papageorgiou (2009)).

Pharmaceutical Product Perishability

Product perishability is another critical issue in pharmaceutical / drug supply chains.

- In a 2003 survey, the estimated loss incurred *due to the expiration of branded products in supermarkets and drug stores was over 500 million dollars.*
- In 2007, in a warehouse belonging to the Health Department of Chicago, *over one million dollars in drugs, vaccines, and other medical supplies were found spoiled, stolen, or unaccounted for.*
- In 2009, CVS pharmacies in California, as a result of a settlement of a lawsuit filed against the company, had to offer promotional coupons to customers who had identified expired drugs, including expired baby formula and children's medicines, *in more than 42 percent of the stores* surveyed the year before.

Pharmaceutical Product Perishability

Other instances of medications sold more than a year past their expiration dates have occurred in other pharmacies across the US.

Certain medications, including insulin, must be stored under appropriate environmental conditions, and exposure to water, heat, humidity or other factors can adversely affect how certain drugs perform in the human body.

It is estimated that 7 out of 10 of the leading pharmaceutical products now require temperature-controlled transportation.

Product Shortages

Ironically, whereas some drugs may be unsold and unused and / or past their expiration dates, *the number of drugs that were reported in short supply in the U.S. in the first half of 2011 had risen to 211 – close to an all-time record* – with only 58 in short supply in 2004.

In 2012, the number of drugs in short supply, both new and long-term, and reflecting medicines crucial to treating cancer, infections, cardiac arrest, premature infants, pain, and more was 456, up from 154 in 2007.

At the end of 2014, there were 97 drug shortages. In the past year there have been shortages of nitroglycerin injections and intravenous saline bags.

Two key prevention strategies, with support of the FDA, that have helped drive this significant decrease in shortages, 1) early notification, and 2) a focus on manufacturing quality.

H1N1 (Swine) Flu

As of May 2, 2010, worldwide, more than 214 countries and overseas territories or communities reported laboratory confirmed cases of pandemic influenza H1N1 2009, including over 18,001 deaths (www.who.int).

Parts of the globe experienced serious flu vaccine shortages, both seasonal and H1N1 (swine) ones, in late 2009.



Some Possible Causes of Shortages

While the causes of many shortages are complex, most cases appear to be related to manufacturers' decisions to cease production in the presence of financial challenges. Quality shortcomings in manufacturing has also been another major issue.

It is interesting to note that, among curative cancer drugs, only the older generic, yet, less expensive, ones, have experienced shortages.

As noted by Shah (2004), pharmaceutical companies secure notable returns solely in the early lifetime of a successful drug, before competition takes place. This competition-free time-span, however, has been observed to be shortening, from 5 years to only 1-2 years.

Economic and Financial Pressures

Pharmaceutical companies were expected to suffer a significant decrease in their revenues as a result of losing patent protection for ten of the best-selling drugs by the end of 2012 (De la Garza (2011)).

These included Lipitor and Plavix, that, in 2011, generated more than \$142 billion in sales, and were expected, over the subsequent five years, to be faced with generic competition.

In 2011, pharmaceutical products valued at more than \$30 billion lost patent protection, with such products generating more than \$15 billion in sales in 2010.

Safety Issues

- More than 80% of the ingredients of drugs sold in the U.S. are made overseas, mostly in remote facilities located in China and India that are rarely – if not ever – visited by government inspectors.
- Supply chains of generic drugs, which account for 75% of the prescription medicines sold in the U.S., are, typically, more susceptible to falsification with the supply chains of some of the over-the-counter products, such as vitamins or aspirins, also vulnerable to adulteration.
- The amount of counterfeit drugs in the European pharmaceutical supply chains has considerably increased.

In the past, product recalls were mainly related to local errors in design, manufacturing, or labeling, *a single product safety issue may result in huge global consequences.*



A Generalized Network Oligopoly Model for Pharmaceutical Supply Chains

The supply chain generalized network oligopoly model has the following novel features:

1. it handles the perishability of the pharmaceutical product through the introduction of arc multipliers;
2. it allows each firm to minimize the discarding cost of waste / perished medicine;
3. it captures product differentiation under oligopolistic competition through the branding of drugs, which can also include generics as distinct brands.

References can be found in our paper, “A Supply Chain Generalized Network Oligopoly Model for Pharmaceuticals Under Brand Differentiation and Perishability,” A.H. Masoumi, M. Yu, and A. Nagurney, *Transportation Research E* **48** (2012), 762-780.

A Generalized Network Oligopoly Model for Pharmaceutical Supply Chains


We consider I pharmaceutical firms, with a typical firm denoted by i .

The firms compete non-cooperatively, in an oligopolistic manner, and the consumers can differentiate among the products of the pharmaceutical firms through their individual product brands.

The supply chain network activities include manufacturing, shipment, storage, and, ultimately, the distribution of the brand name drugs to the demand markets.

Pharmaceutical Firm 1

Pharmaceutical Firm I



A Generalized Network Oligopoly Model for Pharmaceutical Supply Chains

Each pharmaceutical firm i ; $i = 1, \dots, I$, utilizes n_M^i manufacturing plants and n_D^i distribution / storage facilities, and the goal is to serve n_R demand markets consisting of pharmacies, retail stores, hospitals, and other medical centers.

L^i denotes the set of directed links corresponding to the sequence of activities associated with firm i . Also, $G = [N, L]$ denotes the graph composed of the set of nodes N , and the set of links L , where L contains all sets of L_i s: $L \equiv \cup_{i=1, \dots, I} L^i$.

A Generalized Network Oligopoly Model for Pharmaceutical Supply Chains

In the Figure, the first set of links connecting the top two tiers of nodes corresponds to the process of production of the drugs at each of the manufacturing units of firm i ; $i = 1, \dots, I$. Such facilities are denoted by $M_1^i, \dots, M_{n_M^i}^i$, respectively, for firm i .

We emphasize that the manufacturing facilities may be located not only in different regions of the same country but also in different countries.

A Generalized Network Oligopoly Model for Pharmaceutical Supply Chains

The next set of nodes represents the distribution centers, and, thus, the links connecting the manufacturing nodes to the distribution centers are shipment-type links. Such distribution nodes associated with firm i ; $i = 1, \dots, I$ are denoted by $D_{1,1}^i, \dots, D_{n_D^i,1}^i$ and represent the distribution centers that the produced drugs are shipped to, and stored at, before being delivered to the demand markets.

There are alternative shipment links to denote different possible modes of transportation. In the shipment of pharmaceuticals that are perishable, one may wish, for example, to ship by air, but at a higher cost.

A Generalized Network Oligopoly Model for Pharmaceutical Supply Chains

The next set of links connecting nodes $D_{1,1}^i, \dots, D_{n_D,1}^i$ to $D_{1,2}^i, \dots, D_{n_D,2}^i$; $i = 1, \dots, I$ represents the process of storage.

Since drugs may require different storage conditions / technologies before being ultimately shipped to the demand markets, we represent these alternatives through multiple links at this tier.

The last set of links connecting the two bottom tiers of the supply chain network corresponds to distribution links over which the stored products are shipped from the distribution / storage facilities to the demand markets. Here we also allow for multiple modes of shipment / transportation.

How We Handle Perishability

In addition, this fraction need not be the same among various links of the same tier in the supply chain network since different firms and even different units of the same firm may experience non-identical amounts of waste, depending on the brand of drug, the efficiency of the utilized technology, and the experience of the staff, etc.

Also, such multipliers can capture pilferage / theft, a significant issue in drug supply chains.

How We Handle Perishability

We associate with every link a in the supply chain network, a multiplier α_a , which lies in the range of $(0,1]$. The parameter α_a may be interpreted as a throughput factor corresponding to link a meaning that $\alpha_a \times 100\%$ of the initial flow of product on link a reaches the successor node of that link.

Let f_a denote the (initial) flow of product on link a with f'_a denoting the final flow on link a ; i.e., the flow that reaches the successor node of the link after wastage has taken place. Therefore, we have:

$$f'_a = \alpha_a f_a, \quad \forall a \in L. \quad (1)$$

Consequently, the waste / loss on link a , denoted by w_a , which is the difference between the initial and the final flow, can be derived as:

$$w_a = f_a - f'_a = (1 - \alpha_a) f_a, \quad \forall a \in L. \quad (2)$$

How We Handle Perishability

The parameter α_a is assumed to be constant and known a priori. We can construct a total discarding cost function, \hat{z}_a , associated with discarding the medical waste, which is a function of the flow, f_a , and is assumed to be convex and continuously differentiable:

$$\hat{z}_a = \hat{z}_a(f_a), \quad \forall a \in L. \quad (3)$$

How We Handle Perishability

Let x_p represent the (initial) flow of product on path p joining an origin node, i , with a destination node, R_k . The path flows must be nonnegative, that is,

$$x_p \geq 0, \quad \forall p \in P_k^i; i = 1, \dots, I; k = 1, \dots, n_R, \quad (4)$$

where P_k^i is the set of all paths joining the origin node i ; $i = 1, \dots, I$ with destination node R_k .

Also, μ_p denotes the multiplier corresponding to the throughput on path p , defined as the product of all link multipliers on links comprising that path, that is,

$$\mu_p \equiv \prod_{a \in p} \alpha_a, \quad \forall p \in P_k^i; i = 1, \dots, I; k = 1, \dots, n_R. \quad (5)$$

How We Handle Perishability

We define the multiplier, α_{ap} , which is the product of the multipliers of the links on path p that precede link a in that path, as follows:

$$\alpha_{ap} \equiv \begin{cases} \delta_{ap} \prod_{a' < a} \alpha_{a'}, & \text{if } \{a' < a\} \neq \emptyset, \\ \delta_{ap}, & \text{if } \{a' < a\} = \emptyset, \end{cases} \quad (6)$$

where $\{a' < a\}$ denotes the set of the links preceding link a in path p , and \emptyset denotes the null set. In addition, δ_{ap} is defined as equal to 1 if link a is contained in path p , and 0, otherwise. As a result, α_{ap} is equal to the product of all link multipliers preceding link a in path p . If link a is not contained in path p , then α_{ap} is set to zero. If a belongs to the first set of links; i.e., the manufacturing links, this multiplier is equal to 1.

How We Handle Perishability

Hence, the relationship between the link flow, f_a , and the path flows can be expressed as:

$$f_a = \sum_{i=1}^I \sum_{k=1}^{n_R} \sum_{p \in P_k^i} x_p \alpha_{ap}, \quad \forall a \in L. \quad (7)$$

How We Handle Perishability

Note that the arc multipliers may be obtained from historical and statistical data.

They may also, in the case of certain perishable products, be related to an exponential time decay function where the time, in our framework, is associated with each specific link activity (see, for instance, Blackburn and Scudder (2009) and Bai and Kendall (2009)).

For example, Nagurney and Nagurney (2011) constructed explicit arc multipliers for molybdenum, which is used in nuclear medicine, which were based on the physics of time decay for this pharmaceutical product used in cancer and cardiac diagnostics, among other procedures.

How We Handle Perishability

Let d_{ik} denote the demand for pharmaceutical firm i 's brand drug; $i = 1, \dots, I$, at demand market R_k ; $k = 1, \dots, n_R$. The consumers differentiate the products by their brands.

The following equation reveals the relationship between the path flows and the demands in the supply chain network:

$$\sum_{p \in P_k^i} x_p \mu_p = d_{ik}, \quad i = 1, \dots, I; k = 1, \dots, n_R, \quad (8)$$

that is, the demand for a brand drug at the demand market R_k is equal to the sum of all the final flows – subject to perishability – on paths joining (i, R_k) . We group the demands d_{ik} ; $i = 1, \dots, I; k = 1, \dots, n_R$ into the $n_R \times I$ -dimensional vector d .

The Demand Price Functions

A demand price function is associated with each firm's pharmaceutical drug at each demand market. We denote the demand price of firm i 's product at demand market R_k by ρ_{ik} and assume that

$$\rho_{ik} = \rho_{ik}(d), \quad i = 1, \dots, l; k = 1, \dots, n_R. \quad (9)$$

The Total Cost Functions

The total operational cost on link a may, in general, depend upon the product flows on all the links, that is,

$$\hat{c}_a = \hat{c}_a(f), \quad \forall a \in L, \quad (10)$$

where f is the vector of all the link flows. The total cost on each link is assumed to be convex and continuously differentiable.

X_i denotes the vector of path flows associated with firm i ; $i = 1, \dots, I$, where $X_i \equiv \{\{x_p\} | p \in P^i\} \in R_+^{n_{Pi}}$, and $P^i \equiv \cup_{k=1, \dots, n_R} P_k^i$. In turn, n_{Pi} , denotes the number of paths from firm i to the demand markets. Thus, X is the vector of all the firms' strategies, that is, $X \equiv \{\{X_i\} | i = 1, \dots, I\}$.

The Profit Function

The profit function of firm i , denoted by U_i , is expressed as:

$$U_i = \sum_{k=1}^{n_R} \rho_{ik}(d) \sum_{p \in P_k^i} \mu_p x_p - \sum_{a \in L^i} \hat{c}_a(f) - \sum_{a \in L^i} \hat{z}_a(f_a). \quad (11)$$

In lieu of the conservation of flow expressions (7) and (8), and the functional expressions (3), (9), and (10), we may define

$\hat{U}_i(X) = U_i$ for all firms i ; $i = 1, \dots, I$, with the I -dimensional vector \hat{U} being the vector of the profits of all the firms:

$$\hat{U} = \hat{U}(X). \quad (12)$$

Supply Chain Generalized Network Cournot-Nash Equilibrium

In the Cournot-Nash oligopolistic market framework, each firm selects its product path flows in a noncooperative manner, seeking to maximize its own profit, until an equilibrium is achieved, according to the definition below.

Definition 1: Supply Chain Generalized Network Cournot-Nash Equilibrium

A path flow pattern $X^ \in K = \prod_{i=1}^l K_i$ constitutes a supply chain generalized network Cournot-Nash equilibrium if for each firm i ; $i = 1, \dots, l$:*

$$\hat{U}_i(X_i^*, \hat{X}_i^*) \geq \hat{U}_i(X_i, \hat{X}_i^*), \quad \forall X_i \in K_i, \quad (13)$$

where $\hat{X}_i^ \equiv (X_1^*, \dots, X_{i-1}^*, X_{i+1}^*, \dots, X_l^*)$ and $K_i \equiv \{X_i | X_i \in R_+^{n_{Pi}}\}$.*

An equilibrium is established if no firm can unilaterally improve its profit by changing its production path flows, given the production path flow decisions of the other firms.

Next, we present the variational inequality formulations of the Cournot-Nash equilibrium for the pharmaceutical supply chain network under oligopolistic competition satisfying Definition 1, in terms of both path flows and link flows (see Cournot (1838), Nash (1950, 1951), Gabay and Moulin (1980), and Nagurney (2006)).

The Variational Inequality Formulation

Theorem 1

Assume that, for each pharmaceutical firm i ; $i = 1, \dots, I$, the profit function $\hat{U}_i(X)$ is concave with respect to the variables in X_i , and is continuously differentiable. Then $X^ \in K$ is a supply chain generalized network Cournot-Nash equilibrium according to Definition 1 if and only if it satisfies the variational inequality:*

$$-\sum_{i=1}^I \langle \nabla_{X_i} \hat{U}_i(X^*), X_i - X_i^* \rangle \geq 0, \quad \forall X \in K, \quad (14)$$

where $\langle \cdot, \cdot \rangle$ denotes the inner product in the corresponding Euclidean space and $\nabla_{X_i} \hat{U}_i(X)$ denotes the gradient of $\hat{U}_i(X)$ with respect to X_i .

The Variational Inequality Formulation

Variational inequality (14), in turn, for our model, is equivalent to the variational inequality: determine $x^ \in K^1$ such that:*

$$\sum_{i=1}^I \sum_{k=1}^{n_R} \sum_{p \in P_k^i} \left[\frac{\partial \hat{C}_p(x^*)}{\partial x_p} + \frac{\partial \hat{Z}_p(x^*)}{\partial x_p} - \rho_{ik}(x^*) \mu_p - \sum_{l=1}^{n_R} \frac{\partial \rho_{il}(x^*)}{\partial d_{ik}} \mu_p \sum_{p \in P_l^i} \mu_p x_p^* \right] \times [x_p - x_p^*] \geq 0, \quad \forall x \in K^1, \quad (15)$$

where $K^1 \equiv \{x | x \in R_+^{n_P}\}$, and, for notational convenience, we denote:

$$\frac{\partial \hat{C}_p(x)}{\partial x_p} \equiv \sum_{b \in L^i} \sum_{a \in L^i} \frac{\partial \hat{c}_b(f)}{\partial f_a} \alpha_{ap} \text{ and } \frac{\partial \hat{Z}_p(x)}{\partial x_p} \equiv \sum_{a \in L^i} \frac{\partial \hat{z}_a(f_a)}{\partial f_a} \alpha_{ap}. \quad (16)$$

The Variational Inequality Formulation

Variational inequality (15) can also be re-expressed in terms of link flows as: determine the vector of equilibrium link flows and the vector of equilibrium demands $(f^, d^*) \in K^2$, such that:*

$$\begin{aligned} & \sum_{i=1}^I \sum_{a \in L^i} \left[\sum_{b \in L^i} \frac{\partial \hat{c}_b(f^*)}{\partial f_a} + \frac{\partial \hat{z}_a(f_a^*)}{\partial f_a} \right] \times [f_a - f_a^*] \\ & + \sum_{i=1}^I \sum_{k=1}^{n_R} \left[-\rho_{ik}(d^*) - \sum_{l=1}^{n_R} \frac{\partial \rho_{il}(d^*)}{\partial d_{ik}} d_{il}^* \right] \times [d_{ik} - d_{ik}^*] \geq 0, \quad \forall (f, d) \in K^2, \end{aligned} \quad (17)$$

where $K^2 \equiv \{(f, d) | x \geq 0, \text{ and (7) and (8) hold}\}$.

The Variational Inequality Formulation

Variational inequalities (15) and (17) can be put into standard form (see Nagurney (1999)): determine $X^* \in \mathcal{K}$ such that:

$$\langle F(X^*), X - X^* \rangle \geq 0, \quad \forall X \in \mathcal{K}, \quad (18)$$

where $\langle \cdot, \cdot \rangle$ denotes the inner product in n -dimensional Euclidean space. Let: $X \equiv x$ and

$$F(X) \equiv \left[\frac{\partial \hat{C}_p(x)}{\partial x_p} + \frac{\partial \hat{Z}_p(x)}{\partial x_p} - \rho_{ik}(x) \mu_p - \sum_{l=1}^{n_R} \frac{\partial \rho_{il}(x)}{\partial d_{ik}} \mu_p \sum_{p \in P_l^i} \mu_p x_p; \quad p \in P_k^i \right]$$

and $\mathcal{K} \equiv K^1$.

The Variational Inequality Formulation

Similarly, for the variational inequality in terms of link flows, if we define the column vectors: $X \equiv (f, d)$ and $F(X) \equiv (F_1(X), F_2(X))$:

$$F_1(X) = \left[\sum_{b \in L^i} \frac{\partial \hat{c}_b(f)}{\partial f_a} + \frac{\partial \hat{z}_a(f_a)}{\partial f_a}; a \in L^i; i = 1, \dots, l \right],$$

$$F_2(X) = \left[-\rho_{ik}(d) - \sum_{l=1}^{n_R} \frac{\partial \rho_{il}(d)}{\partial d_{ik}} d_{il}; i = 1, \dots, l; k = 1, \dots, n_R \right],$$

and let $\mathcal{K} \equiv K^2$.

Relationship of the Model to Others in the Literature

Relationship of the Model to Others in the Literature

The above model is now related to several models in the literature.

If the arc multipliers are all equal to 1, in which case the product is not perishable, then the model is related to the sustainable fashion supply chain network model of Nagurney and Yu in the *International Journal of Production Economics* **135** (2012), 532-540. In that model, however, the other criterion, in addition to the profit maximization one, was emission minimization, rather than waste cost minimization, as in the model in this paper.



Relationship of the Model to Others in the Literature

If the demands are fixed, and there is a single organization, but there are additional processing tiers, as well as capacity investments as variables, the model is the medical nuclear supply chain design model of Nagurney and Nagurney, *International Journal of Production Economics* (2012).

Relationship of the Model to Others in the Literature

If the demands are fixed, and there is a single organization, but there are additional processing tiers, as well as capacity investments as variables, the model is the medical nuclear supply chain design model of Nagurney and Nagurney, *International Journal of Production Economics* (2012).

If there is only a single organization / firm, and the demands are subject to uncertainty, with the inclusion of expected costs due to shortages or excess supplies, the total operational cost functions are separable, and a criterion of risk is added, then the model above is related to the blood supply chain network operations management model of Nagurney, Masoumi, and Yu, *Computational Management Science* (2012).

Relationship of the Model to Others in the Literature

If the product is homogeneous, and all the arc multipliers are, again, assumed to be equal to 1, and the total costs are assumed to be separable, then the above model collapses to the supply chain network oligopoly model of Nagurney (2010) in which synergies associated with mergers and acquisitions were assessed.



The Original Supply Chain Network Oligopoly Model




Figure 4: Supply Chain Network Structure of the Oligopoly Without Perishability; Nagurney, *Computational Management Science* **7**(2010), 377-401.

Mergers Through Coalition Formation




Figure 5: Mergers of the First $n_{1'}$ Firms and the Next $n_{2'}$ Firms

A Simple Perishable Product Numerical Example

A Simple Perishable Product Numerical Example

Pharmaceutical Firm 1

Pharmaceutical Firm 2




Figure 6: Supply Chain Network Topology for the Pharmaceutical Duopoly in the Illustrative Example

A Simple Perishable Product Numerical Example

In this example, two pharmaceutical firms compete in a duopoly with a single demand market (See Figure). The two firms produce differentiated, but substitutable, brand drugs 1 and 2, corresponding to Firm 1 and Firm 2, respectively.

The total cost functions on the various links of manufacturing, shipment, storage, and distribution are:

$$\hat{c}_1(f_1) = 5f_1^2 + 8f_1, \hat{c}_2(f_2) = 7f_2^2 + 3f_2, \hat{c}_3(f_3) = 2f_3^2 + f_3,$$

$$\hat{c}_4(f_4) = 2f_4^2 + 2f_4,$$

$$\hat{c}_5(f_5) = 3f_5^2 + 4f_5, \hat{c}_6(f_6) = 3.5f_6^2 + f_6, \hat{c}_7(f_7) = 2f_7^2 + 5f_7,$$

$$\hat{c}_8(f_8) = 1.5f_8^2 + 4f_8.$$

The arc multipliers are given by:

$$\alpha_1 = .95, \alpha_2 = .98, \alpha_3 = .99, \alpha_4 = 1.00, \alpha_5 = .99, \alpha_6 = .97,$$

$$\alpha_7 = 1.00, \alpha_8 = 1.00.$$

A Simple Perishable Product Numerical Example

The total discarding cost functions on the links are assumed identical, that is,

$$\hat{z}_a(f_a) = .5f_a^2, \quad \forall a.$$

The firms compete in the demand market R_1 , and the consumers reveal their preferences for the two products through the following nonseparable demand price functions:

$$\rho_{11}(d) = -3d_{11} - d_{21} + 200, \quad \rho_{21}(d) = -4d_{21} - 1.5d_{11} + 300.$$

In this supply chain network, there exists one path corresponding to each firm, denoted by p_1 and p_2 .

A Simple Perishable Product Numerical Example

Thus, variational inequality (15), here takes the form:

$$\begin{aligned} & \left[\frac{\partial \hat{C}_{p_1}(x^*)}{\partial x_{p_1}} + \frac{\partial \hat{Z}_{p_1}(x^*)}{\partial x_{p_1}} - \rho_{11}(x^*)\mu_{p_1} - \frac{\partial \rho_{11}(x^*)}{\partial d_{11}}\mu_{p_1} \times \mu_{p_1}x_{p_1}^* \right] \\ & \quad \times [x_{p_1} - x_{p_1}^*] \\ & + \left[\frac{\partial \hat{C}_{p_2}(x^*)}{\partial x_{p_2}} + \frac{\partial \hat{Z}_{p_2}(x^*)}{\partial x_{p_2}} - \rho_{21}(x^*)\mu_{p_2} - \frac{\partial \rho_{21}(x^*)}{\partial d_{21}}\mu_{p_2} \times \mu_{p_2}x_{p_2}^* \right] \\ & \quad \times [x_{p_2} - x_{p_2}^*] \geq 0, \forall x \in K^1. \end{aligned}$$

A Simple Perishable Product Numerical Example

Under the assumption that $x_{p_1}^* > 0$ and $x_{p_2}^* > 0$, the two expressions on the left-hand side of inequality (27) must be equal to zero, that is:

$$\left[\frac{\partial \hat{C}_{p_1}(x^*)}{\partial x_{p_1}} + \frac{\partial \hat{Z}_{p_1}(x^*)}{\partial x_{p_1}} - \rho_{11}(x^*)\mu_{p_1} - \frac{\partial \rho_{11}(x^*)}{\partial d_{11}}\mu_{p_1} \times \mu_{p_1}x_{p_1}^* \right] \\ \times [x_{p_1} - x_{p_1}^*] = 0,$$

and

$$\left[\frac{\partial \hat{C}_{p_2}(x^*)}{\partial x_{p_2}} + \frac{\partial \hat{Z}_{p_2}(x^*)}{\partial x_{p_2}} - \rho_{21}(x^*)\mu_{p_2} - \frac{\partial \rho_{21}(x^*)}{\partial d_{21}}\mu_{p_2} \times \mu_{p_2}x_{p_2}^* \right] \\ \times [x_{p_2} - x_{p_2}^*] = 0.$$

Since each of the paths flows must be nonnegative, we know that the term preceding the multiplication sign in both of the above must be equal to zero.

A Simple Perishable Product Numerical Example

Calculating the values of the multipliers from (6), and then, substituting those values, as well as, the given functions into (16), we can determine the partial derivatives of the total operational cost and the total discarding cost functions. Furthermore, the partial derivatives of the given demand price functions can be calculated and substituted into the above. Applying (5), the path multipliers are equal to:

$$\mu_{p_1} = \alpha_1 \times \alpha_3 \times \alpha_5 \times \alpha_7 = .95 \times .99 \times .99 \times 1 = .93,$$

$$\mu_{p_2} = \alpha_2 \times \alpha_4 \times \alpha_6 \times \alpha_8 = .98 \times 1 \times .97 \times 1 = .95.$$

Simple arithmetic calculations, with the above substitutions, yield the below system of equations:

$$\begin{cases} 31.24x_{p_1}^* + 0.89x_{p_2}^* = 168.85, \\ 1.33x_{p_1}^* + 38.33x_{p_2}^* = 274.46. \end{cases}$$

A Simple Perishable Product Numerical Example

Thus, the equilibrium solution corresponding to the path flow of brand drugs produced by firms 1 and 2 is:

$$x_{p_1}^* = 5.21, \quad x_{p_2}^* = 6.98.$$

Using (7), the equilibrium link flows can be calculated as:

$$f_1^* = 5.21, \quad f_3^* = 4.95, \quad f_5^* = 4.90, \quad f_7^* = 4.85,$$

$$f_2^* = 6.98, \quad f_4^* = 6.84, \quad f_6^* = 6.84, \quad f_8^* = 6.64.$$

From (8), the equilibrium values of demand for products of the two pharmaceutical firms are equal to:

$$d_{11}^* = 4.85, \quad d_{21}^* = 6.64.$$

Finally, the equilibrium prices of the two branded drugs are:

$$\rho_{11} = 178.82, \quad \rho_{21} = 266.19.$$

Note that, even though the price of Firm 2's product is observed to be higher, the market has a slightly stronger tendency toward this product as opposed to the product of Firm 1.

This is due to the willingness of the consumers to spend more on one product which can be a consequence of the reputation, or the perceived quality, of Firm 2's brand drug.

The Algorithm with Explicit Formulae

The Algorithm

We recall the Euler method, which is induced by the general iterative scheme of Dupuis and Nagurney (1993). Its realization for the solution of the supply chain generalized network oligopoly model with brand differentiation governed by variational inequality (15) induces subproblems that can be solved explicitly and in closed form.

Specifically, iteration τ of the Euler method (see also Nagurney and Zhang (1996)) is given by:

$$X^{\tau+1} = P_{\mathcal{K}}(X^{\tau} - a_{\tau}F(X^{\tau})),$$

where $P_{\mathcal{K}}$ is the projection on the feasible set \mathcal{K} and F is the function that enters the variational inequality problem (18).

The Algorithm

As shown in Dupuis and Nagurney (1993) and Nagurney and Zhang (1996), for convergence of the general iterative scheme, which induces the Euler method, the sequence $\{a_\tau\}$ must satisfy:
$$\sum_{\tau=0}^{\infty} a_\tau = \infty, a_\tau > 0, a_\tau \rightarrow 0, \text{ as } \tau \rightarrow \infty.$$

Conditions for convergence of this scheme as well as various applications to the solutions of network oligopolies can be found in Nagurney and Zhang (1996), Nagurney, Dupuis, and Zhang (1994), Nagurney (2010a), and Nagurney and Yu (2011).

The Algorithm

Explicit Formulae for the Euler Method Applied to the Supply Chain Generalized Network Oligopoly Variational Inequality (15)

The elegance of this procedure for the computation of solutions to our supply chain generalized network oligopoly model with product differentiation can be seen in the following explicit formulae. We have the following closed form expressions for all the path flows $p \in P_k^i, \forall i, k$:

$$x_p^{\tau+1} = \max \left\{ 0, x_p^{\tau} + a_{\tau}(\rho_{ik}(x^{\tau})\mu_p + \sum_{l=1}^{n_R} \frac{\partial \rho_{il}(x^{\tau})}{\partial d_{ik}} \mu_p \sum_{p \in P_l^i} \mu_p x_p^{\tau} - \frac{\partial \hat{C}_p(x^{\tau})}{\partial x_p} - \frac{\partial \hat{Z}_p(x^{\tau})}{\partial x_p}) \right\}.$$

Numerical Cases




Case I

This case is assumed to have occurred in the **third quarter of 2011** prior to the expiration of the patent for Lipitor.

Firm 1 represents a multinational pharmaceutical giant, hypothetically, **Pfizer, Inc.**, which still possesses the patent for **Lipitor**, the most popular brand of cholesterol-lowering drug.

Firm 2, on the other hand, which might represent, for example, **Merck & Co., Inc.**, has been producing **Zocor**, another cholesterol regulating brand, whose patent expired in 2006.

The Pharmaceutical Supply Chain Network Topology for Case I



Case I (cont'd)

The demand price functions were as follows:

$$\rho_{11}(d) = -1.1d_{11} - 0.9d_{21} + 275; \rho_{21}(d) = -1.2d_{21} - 0.7d_{11} + 210;$$

$$\rho_{12}(d) = -0.9d_{12} - 0.8d_{22} + 255; \rho_{22}(d) = -1.0d_{22} - 0.5d_{12} + 200;$$

$$\rho_{13}(d) = -1.4d_{13} - 1.0d_{23} + 265; \rho_{23}(d) = -1.5d_{23} - 0.4d_{13} + 186.$$

The Euler method for the solution of variational inequality was implemented in Matlab. The results can be seen in the following tables.

Link Multipliers, Total Cost Functions and Link Flow Solution for Case I

Link a	α_a	$\hat{c}_a(f_a)$	$\hat{z}_a(f_a)$	f_a^*
1	.95	$5f_1^2 + 8f_1$	$.5f_1^2$	13.73
2	.97	$7f_2^2 + 3f_2$	$.4f_2^2$	10.77
3	.96	$6.5f_3^2 + 4f_3$	$.3f_3^2$	8.42
4	.98	$5f_4^2 + 7f_4$	$.35f_4^2$	10.55
5	1.00	$.7f_5^2 + f_5$	$.5f_5^2$	5.21
6	.99	$.9f_6^2 + 2f_6$	$.5f_6^2$	3.36
7	1.00	$.5f_7^2 + f_7$	$.5f_7^2$	4.47
8	.99	$f_8^2 + 2f_8$	$.6f_8^2$	3.02
9	1.00	$.7f_9^2 + 3f_9$	$.6f_9^2$	3.92
10	1.00	$.6f_{10}^2 + 1.5f_{10}$	$.6f_{10}^2$	3.50
11	.99	$.8f_{11}^2 + 2f_{11}$	$.4f_{11}^2$	3.10
12	.99	$.8f_{12}^2 + 5f_{12}$	$.4f_{12}^2$	2.36
13	.98	$.9f_{13}^2 + 4f_{13}$	$.4f_{13}^2$	2.63
14	1.00	$.8f_{14}^2 + 2f_{14}$	$.5f_{14}^2$	3.79
15	.99	$.9f_{15}^2 + 3f_{15}$	$.5f_{15}^2$	3.12
16	1.00	$1.1f_{16}^2 + 3f_{16}$	$.6f_{16}^2$	3.43
17	.98	$2f_{17}^2 + 3f_{17}$	$.45f_{17}^2$	8.20
18	.99	$2.5f_{18}^2 + f_{18}$	$.55f_{18}^2$	7.25
19	.98	$2.4f_{19}^2 + 1.5f_{19}$	$.5f_{19}^2$	7.97
20	.98	$1.8f_{20}^2 + 3f_{20}$	$.3f_{20}^2$	6.85

Link Multipliers, Total Cost Functions and Solution for Case I (cont'd)

Link a	α_a	$\hat{c}_a(f_a)$	$\hat{z}_a(f_a)$	f_a^*
21	.98	$2.1f_{21}^2 + 3f_{21}$	$.35f_{21}^2$	5.42
22	.99	$1.9f_{22}^2 + 2.5f_{22}$	$.5f_{22}^2$	6.00
23	1.00	$.5f_{23}^2 + 2f_{23}$	$.6f_{23}^2$	3.56
24	1.00	$.7f_{24}^2 + f_{24}$	$.6f_{24}^2$	1.66
25	.99	$.5f_{25}^2 + .8f_{25}$	$.6f_{25}^2$	2.82
26	.99	$.6f_{26}^2 + f_{26}$	$.45f_{26}^2$	3.34
27	.99	$.7f_{27}^2 + .8f_{27}$	$.4f_{27}^2$	1.24
28	.98	$.4f_{28}^2 + .8f_{28}$	$.45f_{28}^2$	2.59
29	1.00	$.3f_{29}^2 + 3f_{29}$	$.55f_{29}^2$	3.45
30	1.00	$.75f_{30}^2 + f_{30}$	$.55f_{30}^2$	1.28
31	1.00	$.65f_{31}^2 + f_{31}$	$.55f_{31}^2$	3.09
32	.99	$.5f_{32}^2 + 2f_{32}$	$.3f_{32}^2$	2.54
33	.99	$.4f_{33}^2 + 3f_{33}$	$.3f_{33}^2$	3.43
34	1.00	$.5f_{34}^2 + 3.5f_{34}$	$.4f_{34}^2$	0.75
35	.98	$.4f_{35}^2 + 2f_{35}$	$.55f_{35}^2$	1.72
36	.98	$.3f_{36}^2 + 2.5f_{36}$	$.55f_{36}^2$	2.64
37	.99	$.55f_{37}^2 + 2f_{37}$	$.55f_{37}^2$	0.95
38	1.00	$.35f_{38}^2 + 2f_{38}$	$.4f_{38}^2$	3.47
39	1.00	$.4f_{39}^2 + 5f_{39}$	$.4f_{39}^2$	2.47
40	.98	$.55f_{40}^2 + 2f_{40}$	$.6f_{40}^2$	0.00

Case I: Result Analysis

The computed equilibrium demands for each of the two brands were:

$$d_{11}^* = 10.32, d_{21}^* = 7.66,$$

$$d_{12}^* = 4.17, d_{22}^* = 8.46,$$

$$d_{13}^* = 8.41, d_{23}^* = 1.69.$$

The incurred equilibrium prices associated with the branded drugs at each demand market were as follows:

$$\rho_{11}(d^*) = 256.75, \rho_{21}(d^*) = 193.58,$$

$$\rho_{12}(d^*) = 244.48, \rho_{22}(d^*) = 189.46,$$

$$\rho_{13}(d^*) = 251.52, \rho_{23}(d^*) = 180.09.$$

Case I: Result Analysis

Firm 1, which produces the top-selling product, captures the majority of the market share at demand markets 1 and 3, despite the higher price. In fact, it has almost entirely seized demand market 3 forcing several links connecting Firm 2 to demand market 3 to have insignificant flows including link 40 with a flow equal to zero.

Firm 2 dominates demand market 2, due to the consumers' willingness to lean towards this product there, perhaps as a consequence of the lower price, or the perception of quality, etc.

The profits of the two firms are:

$$U_1(X^*) = 2,936.52 \text{ and } U_2(X^*) = 1,675.89.$$

A Case Study –Case II


In this case, we consider the scenario in which Firm 1 has just lost the exclusive patent right of its highly popular cholesterol regulator. A manufacturer of generic drugs, say, Sanofi, here denoted by Firm 3, has recently introduced a generic substitute for Lipitor by reproducing its active ingredient Atorvastatin (Smith (2011)). Firm 3 is assumed to have two manufacturing plants, two distribution centers as well as two storage facilities in order to supply the same three demand markets as in Case I (See Figure).

The Pharmaceutical Supply Chain Network Topology for Cases II and III

Pharmaceutical Firm 1

Pharmaceutical Firm 3

Pharmaceutical Firm 2



Case II

The demand price functions for the products of Firm 1 and 2 will stay the same as in Case I. The demand price functions corresponding to the product of Firm 3 are as follows:

$$\rho_{31}(d) = -0.9d_{31} - 0.6d_{11} - 0.8d_{21} + 150;$$

$$\rho_{32}(d) = -0.8d_{32} - 0.5d_{12} - 0.6d_{22} + 130;$$

$$\rho_{33}(d) = -0.9d_{33} - 0.7d_{13} - 0.5d_{23} + 133.$$

Link a	α_a	$\hat{c}_a(f_a)$	$\hat{z}_a(f_a)$	f_a^*
1	.95	$5f_1^2 + 8f_1$	$.5f_1^2$	13.73
2	.97	$7f_2^2 + 3f_2$	$.4f_2^2$	10.77
3	.96	$6.5f_3^2 + 4f_3$	$.3f_3^2$	8.42
4	.98	$5f_4^2 + 7f_4$	$.35f_4^2$	10.55
5	1.00	$.7f_5^2 + f_5$	$.5f_5^2$	5.21
6	.99	$.9f_6^2 + 2f_6$	$.5f_6^2$	3.36
7	1.00	$.5f_7^2 + f_7$	$.5f_7^2$	4.47
8	.99	$f_8^2 + 2f_8$	$.6f_8^2$	3.02
9	1.00	$.7f_9^2 + 3f_9$	$.6f_9^2$	3.92
10	1.00	$.6f_{10}^2 + 1.5f_{10}$	$.6f_{10}^2$	3.50
11	.99	$.8f_{11}^2 + 2f_{11}$	$.4f_{11}^2$	3.10
12	.99	$.8f_{12}^2 + 5f_{12}$	$.4f_{12}^2$	2.36
13	.98	$.9f_{13}^2 + 4f_{13}$	$.4f_{13}^2$	2.63
14	1.00	$.8f_{14}^2 + 2f_{14}$	$.5f_{14}^2$	3.79
15	.99	$.9f_{15}^2 + 3f_{15}$	$.5f_{15}^2$	3.12
16	1.00	$1.1f_{16}^2 + 3f_{16}$	$.6f_{16}^2$	3.43
17	.98	$2f_{17}^2 + 3f_{17}$	$.45f_{17}^2$	8.20
18	.99	$2.5f_{18}^2 + f_{18}$	$.55f_{18}^2$	7.25
19	.98	$2.4f_{19}^2 + 1.5f_{19}$	$.5f_{19}^2$	7.97
20	.98	$1.8f_{20}^2 + 3f_{20}$	$.3f_{20}^2$	6.85
21	.98	$2.1f_{21}^2 + 3f_{21}$	$.35f_{21}^2$	5.42
22	.99	$1.9f_{22}^2 + 2.5f_{22}$	$.5f_{22}^2$	6.00
23	1.00	$.5f_{23}^2 + 2f_{23}$	$.6f_{23}^2$	3.56
24	1.00	$.7f_{24}^2 + f_{24}$	$.6f_{24}^2$	1.66
25	.99	$.5f_{25}^2 + .8f_{25}$	$.6f_{25}^2$	2.82
26	.99	$.6f_{26}^2 + f_{26}$	$.45f_{26}^2$	3.34
27	.99	$.7f_{27}^2 + .8f_{27}$	$.4f_{27}^2$	1.24

Link Multipliers,
Total Cost Functions
and Link Flow Solution
for **Case II**

Link a	α_a	$\hat{c}_a(f_a)$	$\hat{z}_a(f_a)$	f_a^*
28	.98	$.4f_{28}^2 + .8f_{28}$	$.45f_{28}^2$	2.59
29	1.00	$.3f_{29}^2 + 3f_{29}$	$.55f_{29}^2$	3.45
30	1.00	$.75f_{30}^2 + f_{30}$	$.55f_{30}^2$	1.28
31	1.00	$.65f_{31}^2 + f_{31}$	$.55f_{31}^2$	3.09
32	.99	$.5f_{32}^2 + 2f_{32}$	$.3f_{32}^2$	2.54
33	.99	$.4f_{33}^2 + 3f_{33}$	$.3f_{33}^2$	3.43
34	1.00	$.5f_{34}^2 + 3.5f_{34}$	$.4f_{34}^2$	0.75
35	.98	$.4f_{35}^2 + 2f_{35}$	$.55f_{35}^2$	1.72
36	.98	$.3f_{36}^2 + 2.5f_{36}$	$.55f_{36}^2$	2.64
37	.99	$.55f_{37}^2 + 2f_{37}$	$.55f_{37}^2$	0.95
38	1.00	$.35f_{38}^2 + 2f_{38}$	$.4f_{38}^2$	3.47
39	1.00	$.4f_{39}^2 + 5f_{39}$	$.4f_{39}^2$	2.47
40	.98	$.55f_{40}^2 + 2f_{40}$	$.6f_{40}^2$	0.00
41	.97	$3f_{41}^2 + 12f_{41}$	$.3f_{41}^2$	6.17
42	.96	$2.7f_{42}^2 + 10f_{42}$	$.4f_{42}^2$	6.23
43	.98	$1.1f_{43}^2 + 6f_{43}$	$.45f_{43}^2$	3.23
44	.98	$.9f_{44}^2 + 5f_{44}$	$.45f_{44}^2$	2.75
45	.97	$1.3f_{45}^2 + 6f_{45}$	$.5f_{45}^2$	3.60
46	.99	$1.5f_{46}^2 + 7f_{46}$	$.55f_{46}^2$	2.38
47	.98	$1.5f_{47}^2 + 4f_{47}$	$.4f_{47}^2$	6.66
48	.98	$2.1f_{48}^2 + 6f_{48}$	$.45f_{48}^2$	5.05
49	.99	$.6f_{49}^2 + 3f_{49}$	$.55f_{49}^2$	3.79
50	1.00	$.7f_{50}^2 + 2f_{50}$	$.7f_{50}^2$	1.94
51	.98	$.6f_{51}^2 + 7f_{51}$	$.45f_{51}^2$	0.79
52	.99	$.9f_{52}^2 + 9f_{52}$	$.5f_{52}^2$	1.43
53	1.00	$.55f_{53}^2 + 6f_{53}$	$.55f_{53}^2$	1.23
54	.98	$.8f_{54}^2 + 4f_{54}$	$.5f_{54}^2$	2.28

Link Multipliers,
Total Cost Functions
and Solution for **Case II**
(cont'd)

Case II: Result Analysis

The equilibrium product flows of Firms 1 and 2 on links 1 through 40 are identical to the corresponding values in Case I.

When the new product produced by Firm 3 is just introduced, the manufacturers of the two existing products will not experience an immediate impact on their respective demands of branded drugs.

The equilibrium computed demands for the products of Firms 1 and 2 at the demand markets will remain as in Case I, and the equilibrium amounts of demand for the new product of Firm 3 at each demand market is equal to:

$$d_{31}^* = 5.17, \quad d_{32}^* = 3.18, \quad \text{and} \quad d_{33}^* = 3.01.$$

Case II: Result Analysis

The equilibrium prices associated with the branded drugs 1 and 2 at the demand markets will not change, whereas the incurred equilibrium prices of generic drug 3 are as follows:

$$\rho_{31}(d^*) = 133.02, \quad \rho_{32}(d^*) = 120.30, \quad \text{and} \quad \rho_{33}(d^*) = 123.55,$$

which is **significantly lower** than the respective prices of its competitors in all the demand markets.

Thus, the profit that Firm 3 derived from manufacturing and delivering the new generic substitute to these 3 markets is:

$$U_3(X^*) = 637.38,$$

while **the profits of Firms 1 and 2 remain unchanged**.

Case III

The generic product of Firm 3 has now been **well-established** and has affected the behavior of the consumers through the demand price functions of the relatively more recognized products of Firms 1 and 2. The demand price functions associated are now given by:

Firm 1: $\rho_{11}(d) = -1.1d_{11} - 0.9d_{21} - 1.0d_{31} + 192;$

$$\rho_{21}(d) = -1.2d_{21} - 0.7d_{11} - 0.8d_{31} + 176;$$

$$\rho_{31} = -0.9d_{31} - 0.6d_{11} - 0.8d_{21} + 170;$$

Firm 2: $\rho_{12}(d) = -0.9d_{12} - 0.8d_{22} - 0.7d_{32} + 166;$

$$\rho_{22}(d) = -1.0d_{22} - 0.5d_{12} - 0.8d_{32} + 146;$$

$$\rho_{32}(d) = -0.8d_{32} - 0.5d_{12} - 0.6d_{22} + 153;$$

Firm 3: $\rho_{13}(d) = -1.4d_{13} - 1.0d_{23} - 0.5d_{33} + 173;$

$$\rho_{23}(d) = -1.5d_{23} - 0.4d_{13} - 0.7d_{33} + 164;$$

$$\rho_{33}(d) = -0.9d_{33} - 0.7d_{13} - 0.5d_{23} + 157.$$

Link a	α_a	$\hat{c}_a(f_a)$	$\hat{z}_a(f_a)$	f_a^*
1	.95	$5f_1^2 + 8f_1$	$.5f_1^2$	8.42
2	.97	$7f_2^2 + 3f_2$	$.4f_2^2$	6.72
3	.96	$6.5f_3^2 + 4f_3$	$.3f_3^2$	6.42
4	.98	$5f_4^2 + 7f_4$	$.35f_4^2$	8.01
5	1.00	$.7f_5^2 + f_5$	$.5f_5^2$	3.20
6	.99	$.9f_6^2 + 2f_6$	$.5f_6^2$	2.07
7	1.00	$.5f_7^2 + f_7$	$.5f_7^2$	2.73
8	.99	$f_8^2 + 2f_8$	$.6f_8^2$	1.85
9	1.00	$.7f_9^2 + 3f_9$	$.6f_9^2$	2.44
10	1.00	$.6f_{10}^2 + 1.5f_{10}$	$.6f_{10}^2$	2.23
11	.99	$.8f_{11}^2 + 2f_{11}$	$.4f_{11}^2$	2.42
12	.99	$.8f_{12}^2 + 5f_{12}$	$.4f_{12}^2$	1.75
13	.98	$.9f_{13}^2 + 4f_{13}$	$.4f_{13}^2$	2.00
14	1.00	$.8f_{14}^2 + 2f_{14}$	$.5f_{14}^2$	2.84
15	.99	$.9f_{15}^2 + 3f_{15}$	$.5f_{15}^2$	2.40
16	1.00	$1.1f_{16}^2 + 3f_{16}$	$.6f_{16}^2$	2.60
17	.98	$2f_{17}^2 + 3f_{17}$	$.45f_{17}^2$	5.02
18	.99	$2.5f_{18}^2 + f_{18}$	$.55f_{18}^2$	4.49
19	.98	$2.4f_{19}^2 + 1.5f_{19}$	$.5f_{19}^2$	4.96
20	.98	$1.8f_{20}^2 + 3f_{20}$	$.3f_{20}^2$	5.23
21	.98	$2.1f_{21}^2 + 3f_{21}$	$.35f_{21}^2$	4.11
22	.99	$1.9f_{22}^2 + 2.5f_{22}$	$.5f_{22}^2$	4.56
23	1.00	$.5f_{23}^2 + 2f_{23}$	$.6f_{23}^2$	2.44
24	1.00	$.7f_{24}^2 + f_{24}$	$.6f_{24}^2$	1.47
25	.99	$.5f_{25}^2 + .8f_{25}$	$.6f_{25}^2$	1.02
26	.99	$.6f_{26}^2 + f_{26}$	$.45f_{26}^2$	2.48
27	.99	$.7f_{27}^2 + .8f_{27}$	$.4f_{27}^2$	1.31

Link Multipliers,
Total Cost Functions
and Link Flow Solution
for **Case III**

Link a	α_a	$\hat{c}_a(f_a)$	$\hat{z}_a(f_a)$	f_a^*
28	.98	$.4f_{28}^2 + .8f_{28}$	$.45f_{28}^2$	0.66
29	1.00	$.3f_{29}^2 + 3f_{29}$	$.55f_{29}^2$	2.29
30	1.00	$.75f_{30}^2 + f_{30}$	$.55f_{30}^2$	1.29
31	1.00	$.65f_{31}^2 + f_{31}$	$.55f_{31}^2$	1.28
32	.99	$.5f_{32}^2 + 2f_{32}$	$.3f_{32}^2$	2.74
33	.99	$.4f_{33}^2 + 3f_{33}$	$.3f_{33}^2$	0.00
34	1.00	$.5f_{34}^2 + 3.5f_{34}$	$.4f_{34}^2$	2.39
35	.98	$.4f_{35}^2 + 2f_{35}$	$.55f_{35}^2$	1.82
36	.98	$.3f_{36}^2 + 2.5f_{36}$	$.55f_{36}^2$	0.00
37	.99	$.55f_{37}^2 + 2f_{37}$	$.55f_{37}^2$	2.21
38	1.00	$.35f_{38}^2 + 2f_{38}$	$.4f_{38}^2$	3.46
39	1.00	$.4f_{39}^2 + 5f_{39}$	$.4f_{39}^2$	0.00
40	.98	$.55f_{40}^2 + 2f_{40}$	$.6f_{40}^2$	1.05
41	.97	$3f_{41}^2 + 12f_{41}$	$.3f_{41}^2$	8.08
42	.96	$2.7f_{42}^2 + 10f_{42}$	$.4f_{42}^2$	8.13
43	.98	$1.1f_{43}^2 + 6f_{43}$	$.45f_{43}^2$	4.21
44	.98	$.9f_{44}^2 + 5f_{44}$	$.45f_{44}^2$	3.63
45	.97	$1.3f_{45}^2 + 6f_{45}$	$.5f_{45}^2$	4.62
46	.99	$1.5f_{46}^2 + 7f_{46}$	$.55f_{46}^2$	3.19
47	.98	$1.5f_{47}^2 + 4f_{47}$	$.4f_{47}^2$	8.60
48	.98	$2.1f_{48}^2 + 6f_{48}$	$.45f_{48}^2$	6.72
49	.99	$.6f_{49}^2 + 3f_{49}$	$.55f_{49}^2$	3.63
50	1.00	$.7f_{50}^2 + 2f_{50}$	$.7f_{50}^2$	3.39
51	.98	$.6f_{51}^2 + 7f_{51}$	$.45f_{51}^2$	1.41
52	.99	$.9f_{52}^2 + 9f_{52}$	$.5f_{52}^2$	1.12
53	1.00	$.55f_{53}^2 + 6f_{53}$	$.55f_{53}^2$	2.86
54	.98	$.8f_{54}^2 + 4f_{54}$	$.5f_{54}^2$	2.60

Link Multipliers,
Total Cost Functions
and Solution for **Case III**
(cont'd)

Case III: Results

The computed equilibrium demands and sales prices for the products of Firms 1, 2, and 3 are as follows:

$$\begin{aligned}d_{11}^* &= 7.18, & d_{21}^* &= 7.96, & d_{31}^* &= 4.70, \\d_{12}^* &= 4.06, & d_{22}^* &= 0.00, & d_{32}^* &= 6.25, \\d_{13}^* &= 2.93, & d_{23}^* &= 5.60, & \text{and } d_{33}^* &= 3.93.\end{aligned}$$

$$\begin{aligned}\rho_{11}(d^*) &= 172.24, & \rho_{21}(d^*) &= 157.66, & \rho_{31}(d^*) &= 155.09, \\ \rho_{12}(d^*) &= 157.97, & \rho_{22}(d^*) &= 138.97, & \rho_{32}(d^*) &= 145.97, \\ \rho_{13}(d^*) &= 161.33, & \rho_{23}(d^*) &= 151.67, & \text{and } \rho_{33}(d^*) &= 148.61.\end{aligned}$$

The computed amounts of firms' profits:

$$U_1(X^*) = 1,199.87, \quad U_2(X^*) = 1,062.73, \quad \text{and } U_3(X^*) = 980.83.$$

Case III: Result Analysis

As a result of the consumers' growing inclination towards the generic substitute of the previously popular Lipitor, Firm 2 has lost its entire share of market 2 to its competitors, resulting in zero flows on several links. Similarly, Firm 1 now has declining sales of its brand in demand markets 1 and 3.

As expected, the introduction of the generic substitute has also caused remarkable drops in the prices of the existing brands. Interestingly, the decrease in the price of Lipitor in demand markets 2 and 3 exceeds 35%.

Note that simultaneous declines in the amounts of demand and sales price has caused a severe reduction in the profits of Firms 1 and 2. This decline for Firm 1 is observed to be as high as 60%.

Validation of Results: Observations

As noted by Johnson (2011), the market share of a branded drug may decrease by as much as 40%-80% after the introduction of its generic rival. Thus, the model captures the observed decrease in the U.S. market share.

Validation of Results: Observations

As noted by Johnson (2011), the market share of a branded drug may decrease by as much as 40%-80% after the introduction of its generic rival. Thus, the model captures the observed decrease in the U.S. market share.

The reduction in demand and price due to the patent expiration has been observed in market sales. The U.S. sales of Lipitor dropped over 75% in 2012 (Forbes (2012) and Firecepharma (2012)).

Paths Definition and Optimal Path Flow Pattern - Firm 1

O/D Pair (1, R_1)	Path Definition	Path Flow
	$p_1 = (1, 5, 17, 23)$	$x_{p_1}^* = 1.87$
	$p_2 = (1, 6, 18, 26)$	$x_{p_2}^* = 1.46$
	$p_3 = (1, 7, 19, 29)$	$x_{p_3}^* = 1.57$
	$p_4 = (2, 8, 17, 23)$	$x_{p_4}^* = 0.73$
	$p_5 = (2, 9, 18, 26)$	$x_{p_5}^* = 1.17$
	$p_6 = (2, 10, 19, 29)$	$x_{p_6}^* = 0.87$
O/D Pair (1, R_2)	$p_7 = (1, 5, 17, 24)$	$x_{p_7}^* = 0.89$
	$p_8 = (1, 6, 18, 27)$	$x_{p_8}^* = 0.57$
	$p_9 = (1, 7, 19, 30)$	$x_{p_9}^* = 0.66$
	$p_{10} = (2, 8, 17, 24)$	$x_{p_{10}}^* = 0.68$
	$p_{11} = (2, 9, 18, 27)$	$x_{p_{11}}^* = 0.82$
	$p_{12} = (2, 10, 19, 30)$	$x_{p_{12}}^* = 0.71$
O/D Pair (1, R_3)	$p_{13} = (1, 5, 17, 25)$	$x_{p_{13}}^* = 0.60$
	$p_{14} = (1, 6, 18, 28)$	$x_{p_{14}}^* = 0.16$
	$p_{15} = (1, 7, 19, 31)$	$x_{p_{15}}^* = 0.64$
	$p_{16} = (2, 8, 17, 25)$	$x_{p_{16}}^* = 0.49$
	$p_{17} = (2, 9, 18, 28)$	$x_{p_{17}}^* = 0.53$
	$p_{18} = (2, 10, 19, 31)$	$x_{p_{18}}^* = 0.72$


Paths Definition and Optimal Path Flow Pattern - Firm 2

O/D Pair (2, R_1)	Path Definition	Path Flow
	$p_{19} = (3, 11, 20, 32)$	$x_{p_{19}}^* = 1.26$
	$p_{20} = (3, 12, 21, 35)$	$x_{p_{20}}^* = 0.77$
	$p_{21} = (3, 13, 22, 38)$	$x_{p_{21}}^* = 1.51$
	$p_{22} = (4, 14, 20, 32)$	$x_{p_{22}}^* = 1.63$
	$p_{23} = (4, 15, 21, 35)$	$x_{p_{23}}^* = 1.16$
	$p_{24} = (4, 16, 22, 38)$	$x_{p_{24}}^* = 2.12$
O/D Pair (2, R_2)	$p_{25} = (3, 11, 20, 33)$	$x_{p_{25}}^* = 0.00$
	$p_{26} = (3, 12, 21, 36)$	$x_{p_{26}}^* = 0.00$
	$p_{27} = (3, 13, 22, 39)$	$x_{p_{27}}^* = 0.00$
	$p_{28} = (4, 14, 20, 33)$	$x_{p_{28}}^* = 0.00$
	$p_{29} = (4, 15, 21, 36)$	$x_{p_{29}}^* = 0.00$
	$p_{30} = (4, 16, 22, 39)$	$x_{p_{30}}^* = 0.00$
O/D Pair (2, R_3)	$p_{31} = (3, 11, 20, 34)$	$x_{p_{31}}^* = 1.26$
	$p_{32} = (3, 12, 21, 37)$	$x_{p_{32}}^* = 1.05$
	$p_{33} = (3, 13, 22, 40)$	$x_{p_{33}}^* = 0.57$
	$p_{34} = (4, 14, 20, 34)$	$x_{p_{34}}^* = 1.26$
	$p_{35} = (4, 15, 21, 37)$	$x_{p_{35}}^* = 1.29$
	$p_{36} = (4, 16, 22, 40)$	$x_{p_{36}}^* = 0.54$

Paths Definition and Optimal Path Flow Pattern - Firm 3


O/D Pair (3, R_1)	Path Definition	Path Flow
	$p_{37} = (41, 43, 47, 49)$	$x_{p_{37}}^* = 1.87$
	$p_{38} = (41, 44, 48, 52)$	$x_{p_{38}}^* = 1.78$
	$p_{39} = (42, 45, 47, 49)$	$x_{p_{39}}^* = 0.70$
	$p_{40} = (42, 46, 48, 52)$	$x_{p_{40}}^* = 0.68$
O/D Pair (3, R_2)	$p_{41} = (41, 43, 47, 50)$	$x_{p_{41}}^* = 1.61$
	$p_{42} = (41, 44, 48, 53)$	$x_{p_{42}}^* = 1.46$
	$p_{43} = (42, 45, 47, 50)$	$x_{p_{43}}^* = 2.07$
	$p_{44} = (42, 46, 48, 53)$	$x_{p_{44}}^* = 1.90$
O/D Pair (3, R_3)	$p_{45} = (41, 43, 47, 51)$	$x_{p_{45}}^* = 0.84$
	$p_{46} = (41, 44, 48, 54)$	$x_{p_{46}}^* = 0.53$
	$p_{47} = (42, 45, 47, 51)$	$x_{p_{47}}^* = 1.46$
	$p_{48} = (42, 46, 48, 54)$	$x_{p_{48}}^* = 1.33$

Path Flow Trajectories




The Trajectories of Product Flows on Paths $p_1 - p_6$

Path Flow Trajectories




The Trajectories of Product Flows on Paths $p_7 - p_{12}$

Path Flow Trajectories




The Trajectories of Product Flows on Paths $p_{13} - p_{18}$

Path Flow Trajectories




The Trajectories of Product Flows on Paths $p_{19} - p_{24}$

Path Flow Trajectories




The Trajectories of Product Flows on Paths $p_{25} - p_{30}$

Path Flow Trajectories




The Trajectories of Product Flows on Paths $p_{31} - p_{36}$

Path Flow Trajectories



The Trajectories of Product Flows on Paths $p_{37} - p_{42}$


Path Flow Trajectories




The Trajectories of Product Flows on Paths $p_{43} - p_{48}$

Supply Chain Network Competition in Quality

Research on Quality is Related to That on Perishability



In the book, we present supply chain network models and tools to investigate, amongst other topics, information asymmetry, impacts of outsourcing on quality, minimum quality standards, applications to industries such as pharma and high tech, freight services and quality, and the identification of which suppliers matter the most to both individual firms' supply chains and to that of the supply chain network economy.




Summary, Conclusions, and Suggestions for Future Research


- ▶ We emphasized the *importance of product perishability* in a wide range of industries.
- ▶ We developed an *integrated framework for the modeling of competition in pharmaceutical supply chains with brand differentiation and perishability* with outsourcing.
- ▶ The model is formulated and solved as a variational inequality problem.
- ▶ We also related the model to several others in the literatures with applications ranging from medical nuclear supply chains to blood supply chains.
- ▶ The framework *can be applied in numerous situations*, with some minor modifications, to capture oligopolistic competition for perishable and time-sensitive products.

- ▶ In addition, we have been heavily involved in *constructing mathematical models for supply chain networks with quality competition*.
- ▶ Our research in supply chains has also led us to other *time-sensitive products*, such as *fast fashion*.
- ▶ We have also worked on models where guaranteed time of delivery is a strategic variable.
- ▶ We expect that future research will include supply chain network design for robustness and resiliency.

THANK YOU!




The Virtual Center for Supernetworks



Supernetworks for Optimal Decision-Making and Improving the Global Quality of Life

Director's Welcome	About the Director	Projects	Supernetworks Laboratory	Center Associates	Media Coverage	What's New
Downloadable Articles	Visuals	Audio/Video	Books	Commentaries & OpEds	The Supernetwork Sentinel	Congratulations & Kudos



**Amazon Supply Chain Summit
October 2015**

The Virtual Center for Supernetworks is an interdisciplinary center at the Isenberg School of Management that advances knowledge on large-scale networks and integrates operations research and management science, engineering, and economics. Its Director is Dr. Anna Nagurney, the John F. Smith Memorial Professor of Operations Management.

Mission: The Virtual Center for Supernetworks fosters the study and application of supernetworks and serves as a resource on networks ranging from transportation and logistics, including supply chains, and the Internet, to a spectrum of economic networks.

The Applications of Supernetworks Include: decision-making, optimization, and game theory; supply chain management; critical infrastructure from transportation to electric power networks; financial networks; knowledge and social networks; energy, the environment, and sustainability; cybersecurity; Future Internet Architectures; risk management; network vulnerability, resiliency, and performance metrics; humanitarian logistics and healthcare.

Announcements and Notes	Photos of Center Activities	Photos of Network Innovators	Friends of the Center	Course Lectures	Fulbright Lectures	UMass Amherst INFORMS Student Chapter
Professor Anna Nagurney's Blog	Network Classics	Doctoral Dissertations	Conferences	Journals	Societies	Archive

Announcements and Notes from the Center Director
Professor Anna Nagurney

Updated: November 21, 2015


Follow

Professor Anna Nagurney's Blog

RENeW


Research, Education, Networks, and the World:
A Female Professor Speaks

Sustaining the Supply Chain




Mathematical Moments Podcast

PBS VIDEO




America Revealed

New Book




Networks Against Time

Photos of Center Activities



The Braess Paradox Translation



Information Photos

Publications

On a Paradox of Traffic Planning

Environmental Impact Assessment of Transportation Networks with Degradable Links in an Era of Climate Change

Anna Nagurney*, Qiong Qiong*, and Ludovic N. Nguyen*

For more information, see: <http://supernet.isenberg.umass.edu>

Anna Nagurney

Supply Chain Networks Against Time